As mental health continues to dominate conversations, the emerging psychedelics industry has found itself in the spotlight. We at Fort Lauderdale and Aspen-based public relations and marketing agency Durée & Company understand the many misconceptions surrounding the NeuroWellness space. And while our psychedelics practice area continues to grow with clients, the opportunity is ripe for education and reframing existing thought patterns. With the psychedelic drugs market projected to reach $6.85 billion by 2027, we are working with clients to end the stigma and communicate the endless possibilities this industry holds.
For many, the word psychedelics immediately conjures images of psilocybin and other entheogens (mushrooms), but there are many other substances used in the psychedelic space, including Ketamine.
Below, we’ve compiled the top five facts on Ketamine and psychedelics:
1. Ketamine has been around for decades.
Ketamine was first synthesized in 1962 by Calvin Stevens at the Parke Davis Laboratories. It was originally developed as a derivative of PCP. It received its patent in 1966 and became available by prescription in 1969.
2. Ketamine is currently the only psychedelic drug that is FDA-approved.
As a result, it has emerged as the “gateway drug” into the emerging psychedelic industry. Ketamine is a dissociative anesthetic and is listed as a schedule III drug in the Controlled Substances Act. It works on specific group of cells in the brain called NMDA receptors. While the FDA approved it as an anesthetic, many doctors use it off-label for mental and behavioral health conditions.
3. Ketamine is often used off-label for various mental and behavioral health conditions.
In today’s modern medicine, we use ketamine to treat depression, PTSD, addiction, and anxiety. When administered for mental or behavioral health conditions, it generally accompanies psychotherapy. A growing number of ketamine clinics are popping up in the U.S. as more and more individuals look to alternative methods of treatment.
4. Ketamine Infusion Therapy is quickly gaining in popularity.
Dustin Robinson, Esq., CPA, managing principal of Iter Investments, an investment firm that deploys capital in and around the burgeoning psychedelic industry; and co-founder of Psychedelic Law, a nonprofit organization focused on psychedelic legal reform, shares that there is no official protocol for ketamine therapy and each clinic has its own way of administering ketamine, either through IV, intramuscular shot or lozenge. For most patients, the process begins with meeting with a doctor to discuss their conditions. If deemed a candidate for therapy, they receive a prescription. Patients then embark on sessions that include speaking with a trained therapist.
5. Ketamine as a treatment method continues to evolve.
Ketamine psychedelics create neuroplasticity in the brain. This allows patients to process trauma in new and healthy ways and experience relief from depression and physical pain. However, we need more research. Some schools of thought lean toward microdosing. Others believe in experiencing larger dosages. In that regard, the future is very promising. There is great potential for companies to develop various products and treatment options that address a wide range of mental health issues.
Whether you’re an established or developing psychedelics company, we have the know-how to help you craft marketing messages in this emerging industry. Visit us at Psychedelicpr.com or call 954-723-9350. Discover how we can establish your communication goals, build the right press campaign, and deliver smart messaging into the hands of media and consumers.
About Durée & Company, Inc.
Durée & Company, Inc. is an award-winning, full-service public relations, marketing and special events firm founded in 1999. The firm has offices in Fort Lauderdale, Florida, and Aspen, Colorado. Durée & Company serves the corporate, agency and nonprofit arenas for local, national and international clients. Services include public relations, social media, marketing, digital marketing, content development, advertising, special events, branding, radio promotions, affiliate marketing and more. Durée & Company clients include well-known names in yachting, business, real estate, hospitality, travel, health and wellness, psychedelics and cannabis, art and culture, fashion, nonprofit organizations, legal and professional services. Durée & Company is a member of PR Boutiques International™ (PRBI), an international network of boutique PR firms. To learn more, call 954-723-9350; go to dureeandcompany.com; or visit its specialized cannabis site at cannabismarketingpr.com, or its new psychedelics-specific site at psychedelicpr.com. Join the social conversation and follow Durée & Company on Facebook, Instagram, Twitter, YouTube and LinkedIn at @DureeCoPR.
